Association of TB treatment initiation delay with clinical severity and risk of transmission among pulmonary tuberculosis patients in Tigray, Northern Ethiopia: Cross-sectional study

CURRENT STATUS: UNDER REVIEW

BMC Infectious Diseases ▼ BMC Series

kiros Tedla
Mekelle University College of Health Sciences

kirosmerry12@gmail.com Corresponding Author
ORCID: https://orcid.org/0000-0003-1566-7038

Girmay Medhin
Addis Ababa City

Gebretsadik Berhe
Mekelle University

Afework Mulgeta
Mekelle University

Nega Berhe
Addis Ababa University

DOI:
10.21203/rs.3.rs-15737/v1

SUBJECT AREAS
Infectious Diseases

KEYWORDS
Tuberculosis, clinical severity, risk of transmission, cross-sectional, Tigray, Ethiopia
Abstract

Background Delayed treatment initiation of tuberculosis (TB) increases disease progression and development of complications which may lead to a higher risk of transmission, clinical severity and increased mortality. But, published evidences that investigated the effect of delayed initiation of treatment on clinical severity and risk of transmission of pulmonary tuberculosis patients is scarce in Tigray, Northern Ethiopia.

Objective To investigate the association of delayed treatment initiation of Pulmonary Tuberculosis with clinical severity and risk of transmission. Methods In this cross-sectional study design, a total of 875 newly diagnosed adult pulmonary tuberculosis patients were recruited from 21 health facilities from October 2018 to October 2019. Health facilities were selected by simple random sampling method and the study participants were enrolled consecutively. Data were collected using questionnaires through face-to-face interviews of patients within the first 2 weeks of treatment initiation. Clinical severity was assessed by Bandim tuberculosis score and risk of transmission was assessed by smear positivity or lung cavitations. Data were analyzed using SPSS version 21 software program. Logistic regression analysis was used to ascertain the association of delay with clinical severity and risk of transmission. P-value of less than 0.05 was reported as being statistically significant.

Results Those who had initiating treatment without delay and those who were initiated treatment after a medium delay of 31 to 60 days were significantly associated with decreased clinical score compared to those who initiated treatment after a delay of more than two months. Compared with patients who were initiated treatment within one month, the risk of transmission was greater for delay of 30-60 days and above 60 days. Patients having more than 3 family members have higher risk to transmit TB as compared to those who have maximum of 3 family members. Whereas, patients having at least two rooms and being HIV negative have lower risk to transmit TB compared to their counter patients.

Conclusion Narrowing the gap between initial occurrence of TB symptoms and treatment initiation is the way forward to improve clinical courses of TB patients and to reduce the risk of transmission of TB
to other people from these patients.

Introduction

Delayed treatment initiation of tuberculosis (TB) has a potential to increase the risk of morbidity and mortality because of disease progression and development of complications (1). This rapid disease progression also increase disease transmission within the community and creates favorable condition for TB epidemic (2, 3). Most transmissions occur between the appearance of cough and initiation of treatment as patients become more contagious with prolonged because of highest bacillary numbers on sputum smears (4).

TB delay can be due to patient delay (late presentation with symptoms), health provider delay (failure of the health system to diagnosis tuberculosis) or total treatment delay (delay due to late presentation and late diagnosis of tuberculosis) (5). In a systematic review of delays in the diagnosis of pulmonary TB, the mean total delay ranged from 25 to 185 days, with patient and health system delay contributing roughly equally (6). Few studies have explored the effects of treatment initiation delay of tuberculosis (TB) patients on the risk of infection among their close contacts, clinical severity, and treatment outcome (7, 8). Studies had also reported the relationship between duration of total delay of smear-positive TB patients and TB infection with a turning point at 30 days after which the risk of TB infection and clinical severity increased significantly (1, 5, 9). There are also contradicting results showing that delay was not related with increased transmission (10, 11).

In Ethiopia where TB is a major public health problem, TB patient’s treatment initiation ranges from 60–120 days (12, 13). The median patient and provider delay were 20–90 days and 6–34 days (12–16), respectively and there is also a fourfold-difference in the time of first contact and diagnosis (12). A prevalence survey in Ethiopia had also indicated that two-thirds of active TB cases were not detected timely (17). In Tigray, northern Ethiopia the median patient delay of smear-positive patients was 90 days, while the overall median health service delay was 9 days (13). Previous studies did not investigate the effect of total delay on the risk of transmission and clinical severity in Ethiopia which would be important for setting interventions to successfully control TB. The aim of the current study was to investigate if the delay in treatment initiation is associated with the risk of transmission and
Methodology

Study area

The study was conducted in two zones (Mekelle and Eastern zones) of Tigray Region, Northern Ethiopia. Mekelle is the Regional capital which is located 778km from Addis-Ababa. The region has seven administrative zones: comprising a total of 53 Weredas (districts) and 673 Tibias (sub-districts). The population is above 5.3 million which is about 6% of the total population of Ethiopia and the rate of urbanization is about 20% per year. Economically active age group accounts for about 51.8% of the total population, 95.5% of the population are Orthodox Christians, 4.1% are Muslims and 0.4% are Catholics (18). There are 712 health posts, 214 health centers and 38 hospitals (1 specialized hospital, 15 general hospitals, 22 primary hospitals) in the region. There are also well-organized community-based structures that support the health system at the grass-root level (health extension workers and women development army). The private health sector also plays a significant role in relieving the burden of the patient load from the public facilities with strong policy support (19, 20). Currently, almost all health facilities are providing directly observed short-course tuberculosis treatment by trained health workers (TB focal persons). The program was introduced in all hospitals, health centers and in most of the health posts for the past years (19).

Study design, population, period and inclusion

A cross-sectional survey was conducted to investigate the effect of total delay of PTB patients on clinical severity and risk of transmission in health facilities of two zones of Tigray Region, Northern Ethiopia. Study participants were bacteriologically positive or x-ray positive pulmonary tuberculosis new cases during one year period (i.e. October 2018 to October 2019) in the health facilities of the two zones of the Tigray region. PTB patients whose age is 18 years and above, with no previous history of TB, non-MDR-TB cases and who are diagnosed and initiated treatment within the study settings were included in the study.

Sample size

In calculating the sample size that enable us to estimate the effect of delay on clinical severity and
risk of transmission, we considered 95% confidence interval, 80% power, equal number of exposed and non-exposed (delay was exposor). The calculated sample size for the objective was 850 and we have considered 425 TB patients as non-exposed and the remaining 425 as exposed.

**Recruitment of study participants**

Out of the seven zones of the region, two zones (i.e. Eastern zone and Mekelle zone) were selected because of their proximity to the research Institute where the TB culture is performed, and logistical reasons that emanates from the need to have frequent visit to the study sites. Furthermore, the only functional specialized hospital is located in Mekelle. Within the selected zones, there were 26 health centers and 6 hospitals that reported an average monthly cases of 3 and above in the years 2016/2017 and 2017/18 (20). Hence, of the 26 health centers and 6 hospitals, 16 were selected by lottery method and five hospitals were included in the study excluding one hospital as it become for ophthalmological service only. The planned sample size was proportionally allocated to each health facility based on the average number of TB cases reported by the facility in the prior two years. Study participants within each facility were consecutively enrolled until the allocated sample size was attained.

**Data collection**

The data collection tool was drafted from previously tested instruments and from reviewed literature (12, 21, 22) and then modified to fit to the context of the research interest. Study participants were identified during their treatment start and invited for consultation and enrolment. The samples for laboratory investigations were collected before treatment initiation. Data were collected on socio-demographic and lifestyle factors, clinical and diagnosis related factors, outcome measurement using Bandim TB score, and measurement of risk of transmission as described below.

**Socio-demographic and lifestyle data:** Background data collected from study participants include gender, age, residence, occupation, marital status, education, family size, income as indebted (poor), income=expense, and saving; smoking history as smoker and non-smoker, and alcohol intake (Yes, No).

**Clinical and diagnostics data:** Clinical examination and interviews of patients were carried out at
recruitment or inclusion. During this time, symptoms (respiratory symptoms, constitutional symptoms, or both), smear status (as positive and negative), pulmonary cavity by chest x-ray (yes/no), and patient delay duration by (<30 days, 31–60 days, and >60 days) were collected. Respiratory symptoms included dyspnea, hemoptysis, cough, or expectoration while constitutional symptoms included malaise, loss of appetite, weight loss, fatigue, fever, chills, chest pain or night sweats.

Smear microscopy of all the study participants was done at three GeneXpert sites of the study area. Three slides per individual were prepared and examined by two laboratory technologists independently. X-ray of the study participants was done in five of the study hospitals who have X-ray machine. These results were examined by a medical doctors specialized in radiology.

**Bandim TB score:** Clinical severity was assessed by the Bandim TB score (8). The Bandim TB score is a newly developed tool to assess clinical status of patients with TB. Its value is expressed as a numeric index based on cough, hemoptysis, dyspnoea, chest pain, night sweating, anemic conjunctivae, tachycardia, positive lung auscultation, increased temperature, body mass index (BMI) and middle-upper arm circumference (MUAC). A Bandim TB scores ≥8 correlates with mortality and lower TB score correlates with favorable outcomes, with cure and treatment success (23, 24). In these studies and in other settings (8) severe TB was defined as TB score ≥8, which has a strong predictive capacity for mortality.

**Scoring and severity classes:** The score was based on 11 clinical variables (i.e. cough, hemoptysis, dyspnoea, chest pain and night sweating, anemic conjunctivae, tachycardia, positive lung auscultation, increased temperature, body mass index (BMI<16 and BMI<18) and middle-upper arm circumference (MUAC<200mm and MUAC<220mm). Each of the 11 variables is scored 0/1 point; the total score was generated resulting the maximum score of 13 points. For all variables examined and used in the score, missing values were coded as zero. The patients were classified into two severity classes as TB score <8 as having less severe and TB score having ≥8 as having a higher severity class.

**Measurement of risk of transmission and definitions**
In this study sputum smear positivity and presence of pulmonary cavity were used as proxy measures for the risk of TB transmission (22, 25, 26). Patients who were smear-positive and had cavitation or smear-positive but had no lung cavitations or smear-negative but had lung cavitation was considered as having risk of transmission. Whereas those patients who were smear-negative and had no lung cavitations were considered as having no risk of transmission. Lung cavitations were defined as the presence of at least one cavity on a chest radiograph taken during the episode of TB (25). Total delay is the time period from the onset of TB symptoms to first start of anti-TB treatment and classified as <30 days, 31-60 days and >60 days.

**Data quality and management**

The questionnaire was pretested before the actual data collection. During sample collection for laboratory investigation, patients were advised to submit thick sputum rather than saliva and the sputum sample was collected as per standards (27). Before smearing, specimens were assessed macroscopically for quality and recorded as purulent with whitish color or bloody. The study numbers or codes were covered with wrap around stickers before microscopy. As part of internal quality control (IQC), all the positive slides and randomly selected 50% of negative slides were re-examined by a different laboratory technologist.

**Data analysis**

Data was computerized and analyzed using SPSS version 21. For categorical variables, univariate analysis was performed by using frequencies and percentages whereas mean or standard deviation was employed for continuous variables. Normality was checked for those continuous variables and the total treatment initiation delay was not normally distributed. Hence, Mann-Whitney U and Kruskal-Wali’s tests were used to compare median delay across the clinical spectrum of the study participants. Initially bivariate logistic regressions was used to model association of pre-specified characteristics and the odds of delayed treatment initiation and then those variables with p-value of at most 0.2 were entered into the multivariate model. A comparison of the proportion of smear-positive tuberculosis and the presence of a pulmonary cavity (risk of transmission) with the duration of patient delay was modeled using a multivariate logistic regression model. Similarly, the association
between clinical severity and the total delay was modeled using multivariate logistic regression. In both logistic regression models the goodness of fit was checked using Hosmer and Lemeshow test. In all analysis any result with the p-value less than 5% was considered as being statistically significant.

Result

Characteristics of the study participants

A total of 875 pulmonary tuberculosis patients were included in this study with a response rate of 100%. The mean ages of the participants were 38.2 (sd=15.1) with a median age of 35 years. From the total respondents, 58.1% were males, 54.5% were from urban areas, 27.2% were farmers, 21.6% were housewives, 18.9% were employed, 10.4% were daily laborer, 11.4% were of students and the remaining 10.5% were Unemployed. In terms of socio-economic status, 37.7% were poor (living in debt), 35.6% had income equal to their expense (had medium income) and the remaining 25.8% earned for covering their expenses and savings. With regard to education, 39.9% were illiterate, 37.1% primary school (1-8 grade), 12.5% secondary school (9-12 grade) and 10.5% completed college and above. Regarding marital status, 55.1% were married, 8% were divorced or widowed and 26.7% were single. Of all the study participants 36.6% were AFB positive, 88.2% were GeneXpert positive and 45.5% had suggestive X-ray (like cavitations in the lung).

Self-reported clinical symptoms and other clinical profiles

The major self-reported clinical symptoms were cough (99.2%), and fever (48.6%). Of all the study participants 28.7% and 26.6% had a BMI of below 18 and 16, respectively. Similarly, 39.6% had MUAC below 220mm and 23.5% had MUAC measurement of below 200mm. The clinical score of 61.6% of the study participants was lower than eight (Table 1)

Table 1: self-reported clinical symptoms and other clinical profile of the study participants from selected health facilities of two zones of Tigray, Northern Ethiopia, October 2018 to October 2019
| Variable | Number (N=875) | Percent |
|----------|---------------|---------|
| **Self reported clinical symptoms** | | |
| Symptoms | | |
| cough | 868 | 99.2 |
| fever | 425 | 48.6 |
| chest pain | 389 | 44.5 |
| weight loss | 398 | 45.5 |
| haemoptysis | 204 | 23.3 |
| others | 449 | 51.3 |
| **Other clinical profiles** | | |
| Presence of other chronic diseases<sup>b</sup> (excluding HIV) | 23 | 2.6 |
| Yes | 852 | 97.4 |
| No | 776 | 88.7 |
| HIV status | | |
| Pos | 99 | 11.3 |
| Neg | 776 | 88.7 |
| BMI | | |
| Normal (>18) | 251 | 28.7 |
| 16-18 | 233 | 26.6 |
| <16 | 391 | 44.7 |
| MUAC (in MM) | | |
| Normal (>220) | 346 | 39.6 |
| 200-220 | 323 | 36.9 |
| ≤200 | 206 | 23.5 |
| Clinical score | | |
| <8 | 445 | 50.9 |
| ≥8 | 430 | 49.1 |

<sup>a</sup> Sweating, loss of appetite, fatigue, chill, malaise. <sup>b</sup> diabetes, arthritis, epilepsy, chronic liver disease, Visceral leishmaniasis, COPD; BMI (Body Mass Index); MUAC (Mid-Upper Arm Circumference)

### Behavioral And Environmental Factors Of The Study Participants

Significant proportion of the study participants had history of alcohol intake and lives in crowded situation (large family living in small number of rooms) and smoking, respectively. Prevalence of reporting history of smoking and contact with known TB patients is not very large (Table 2).

**Table 2**

Behavioral and environmental factors of the study participants in selected health facilities of two zones of Tigray, Northern Ethiopia, October 2018 to October 2019

| Variable | Number (N = 875) | Percent |
|----------|------------------|---------|
| Behavioral and environmental factors | | |
| Alcohol use | | |
| Yes | 464 | 53 |
| No | 411 | 47 |
| History of smoking | | |
| Yes | 786 | 89.8 |
| No | 128 | 13.3 |
| Previous TB contact | | |
| Yes | 477 | 54.5 |
| No | 398 | 45.5 |
| Family size | | |
| 1-3 | 358 | 40.9 |
| >3 | 517 | 59.1 |
| Number of rooms | | |
| <2 | | |
| ≥2 | | |

The effect of total delay on clinical severity and risk of transmission

### The Effect Of Total Delay On Clinical Severity
The median total delay of the study participants was 62 days with an inter-quartile range of 16–221 days. Of all the study participants 26.2% came to a health facility and got diagnosis and treatment within 30 days and of those who delayed for more than 60 days, 80% had a clinical score of eight and above. The difference in median total delay was associated with patients having hemoptysis, fever, chest pain, weight loss and others like night sweating or other constitutional symptoms (Kruskal-Wallis test; P < 0.05; Mann-Whitney test; P < 0.05) (see Table 3).

Table 3
Non-parametric test results of total delay and clinical profile of TB cases in two zones of Tigray, Northern Ethiopia, October 2018 to October 2019

| Variable      | Total delay | P value |
|---------------|-------------|---------|
|               | Median      |         |
| Cough         |             |         |
| Yes           | 59          | 0.518   |
| No            | 62          |         |
| BMI           |             | 0.105   |
| <16           | 69          |         |
| 16–18         | 55          |         |
| >18           | 54          |         |
| Hemoptysis    |             | < 0.001 |
| Yes           | 147         |         |
| No            | 40          |         |
| Chest pain    |             | < 0.001 |
| Yes           | 74          |         |
| No            | 46          |         |
| Weight loss   |             | < 0.001 |
| Yes           | 83          |         |
| No            | 41          |         |
| Fever Others  |             | < 0.001 |
| Yes           | 74          |         |
| No            | 43          |         |
| MUAC (in MM)  |             | 0.134   |
| <200          | 69          |         |
| 200–2200      | 49          |         |
| >2200         | 61          |         |

In multivariate logistic regression analysis (Table 4), those who had not delayed to initiate treatment (AOR = 0.04, 95% CI 0.04–0.11) and those who were initiated treatment after medium delay or from 30 to 60 days (AOR = 0.17, 95% CI 0.06–0.15) were significantly associated with decreased clinical score or mild disease compared to those who initiated treatment after delay for more than two months.
Table 4
Clinical severity score and associated factors among study participants in selected health facilities of two zones of Tigray, Northern Ethiopia, October 2018 to October 2019

| Variables               | Clinical severity | COR       | AOR       |
|-------------------------|-------------------|-----------|-----------|
|                         | Mild (< 8)        | Severe (≥ 8) |           |
| Sex                     |                   |           |           |
| Female                  | 229               | 138       | 0.68(0.81–1.4) | 0.9(0.64–1.27) |
| Male                    | 310               | 198       | 1.00      | 1.00       |
| Age                     |                   |           |           |
| 18–34                   | 139               | 79        | 0.58(0.36–0.94) | 0.58(0.32–1.03) |
| 35–44                   | 254               | 148       | 0.57(0.34–0.95) | 0.61(0.33–1.13) |
| 45–54                   | 93                | 67        | 0.64(0.38–1.1)  | 0.55(0.29–1.03) |
| ≥ 55                    | 42                | 53        | 1.00      | 1.00       |
| Income                  |                   |           |           |
| Indebt                  | 313               | 114       | 1.4(1.01–2.05) | 1.3(0.86–2.03) |
| Income = expense saving | 204               | 128       | 1.2(0.85–1.61) | 0.96(0.65–1.4)  |
| 122                     |                   | 94        | 1.00      | 1.00       |
| Delay in days           |                   |           |           |
| No delay (≤ 30)         | 233               | 32        | 0.07(0.05–0.11) | 0.04(0.04–0.11) |
| Medium delay (31–60)    | 112               | 74        | 0.09(0.06–0.15) | 0.17(0.06–0.15) |
| Long delay (> 60)       | 147               | 277       | 0.91(0.59–1.4)  | 0.91(0.54–1.54) |
| HIV status              |                   |           |           |
| Positive                | 147               | 36        | 1.00      | 1.00       |
| Negative                | 300               | 300       | 0.91(0.50–1.42) | 1.4(0.81–2.41) |
| Smoking history         |                   |           |           |
| Yes                     | 53                | 36        | 0.91(0.50–1.42) | 1.4(0.81–2.41) |
| No                      | 486               | 300       | 1.00      | 1.00       |
| Alcohol consumption     |                   |           |           |
| Yes                     | 300               | 164       | 0.76(0.58–0.99) | 0.84(0.61–1.17) |
| No                      | 239               | 172       | 1.00      | 1.00       |

COR = crude odds ratio, AOR = adjusted odds ratio.

The effect of delay on the risk of TB transmission

In multivariate logistic regression analysis (Table 5), the risk of transmission was 4.2 fold (95%CI, 2.82-6.01 pv < 0.001) in a group that delayed for 30–60 days and 6.2 fold (95%CI 4.32–8.83, pv < 0.001) for those who delayed for more than 60 days as compared to patients who were initiated treatment within one month. Similarly having more than 3 family members has 1.6 fold (95%CI 1.16–2.14) risk of transmission compared to those who have at most three family members. Whereas, having lower number of rooms and being HIV negative were more likely to present with a lower risk of transmission Whereas, having two and above a number of rooms and being HIV negative were less likely to present with a lower risk of transmission by 55% (95%CI 0.33–0.61) and 43% (95%CI 0.36–0.91) compared to those who have one room and HIV positive TB patients, respectively.
### Table 5
Risk of tuberculosis transmission among study participants in selected health facilities of two zones of Tigray, Northern Ethiopia, October 2018 to October 2019

| Variables                        | Risk of transmission | Odds ratio (OR) | Crude OR | Adjusted OR |
|----------------------------------|----------------------|-----------------|----------|-------------|
| Sex                              |                      |                 |          |             |
| Male                             | 250                  | 258             | 1.00     | 1.00        |
| Female                           | 171                  | 196             | 1.1(0.85–1.54) | 0.8(0.59–1.31) |
| Age                              |                      |                 |          |             |
| 18–34                            | 199                  | 203             | 1.00     | 1.00        |
| 35–44                            | 100                  | 118             | 1.1(0.66–1.71) | 0.63(0.35–1.15) |
| 45–54                            | 79                   | 92              | 1.2(0.52–1.7) | 1.1(0.61–1.92) |
| ≥ 55                             | 43                   | 41              | 1.2(0.72–2.1) | 1.2(0.68–2.16) |
| Educational status               |                      |                 |          |             |
| No formal education              | 178                  | 178             | 1.00     | 1.00        |
| Primary education                | 161                  | 164             | 0.65(0.41–1.03) | 0.4(0.22–0.81) |
| Secondary education              | 45                   | 64              | 0.69(0.43–1.1) | 0.7(0.38–1.3) |
| College and above                | 37                   | 55              | 0.96(0.54–1.68) | 0.9(0.52–1.93) |
| Family size                      |                      |                 |          |             |
| 1–3                              | 196                  | 202             | 1.00     | 1.00        |
| > 3                              | 225                  | 252             | 1.07(0.83–1.42) | 1.6(1.16–2.14) |
| Number of rooms                  |                      |                 |          |             |
| < 2                              | 212                  | 146             | 1.00     | 1.00        |
| ≥ 2                              | 209                  | 308             | 0.47(0.36–0.62) | 0.45(0.33–0.61) |
| HIV status                       |                      |                 |          |             |
| Positive                         | 57                   | 42              | 1.00     | 1.00        |
| Negative                         | 364                  | 412             | 0.65(0.43–0.99) | 0.57(0.36–0.91) |
| Delay in days                    |                      |                 |          |             |
| No delay (≤ 30)                  | 68                   | 197             | 1.00     | 1.00        |
| Medium delay (31–60)             | 67                   | 119             | 3.7(2.56–5.29) | 4.2(2.82–6.01) |
| Long delay (> 60)                | 286                  | 138             | 6(4.26–8.46) | 6.2(4.32–8.83) |

OR = odds ratio, * indicates statistically significant variables with P-value less than 0.05

### Discussion

Significant association of delayed treatment initiation in the current study with clinical severity is in line with previous studies in Guinea Bissau (21, 28, 29), Ghana (30), Italy (31) and Spain (6). In Guinea Bissau the proportion of clinical severity was higher among patients who had long and very long delays. The study in Ghana (30) indicated that a higher risk of hospitalization for TB patients was associated with longer treatment delay. The studies in Italy and Spain shown that delayed TB patients to initiate treatment had resulted in more severe clinical presentation and extensive disease condition (31, 7). This might be because the bacteria had got time to multiply, which would lead to further infection and this also allows the MTB to continue growing and overwhelm the cells it has infected which would be resulted in worse clinical symptoms like the presence of a mixture of blood and sputum in the lungs over time (32). This implies the need of interventions targeted to those delayed treatment initiated patients while they are on follow up.

Compared with patients who initiated treatment within one month, the odds of patients presenting with smear-positive tuberculosis and the pulmonary cavity or risk of transmission was higher among
patients who delayed treatment initiation beyond a month. This finding is consistent with other studies from the USA (33) and China (22) in which delay was associated with increased smear positivity and lung cavitations. Thus, the presence of a higher proportion of smear positivity and lung cavitations among delayed TB patients indicates that delayed TB patients had increased risk of transmission. This is supported by previous studies (25, 26) which showed that TB patients with smear positivity and lung cavitations had a higher risk of transmission compared to smear-negative and those who had no lung cavitations. This could be due to a long duration of delay that would affect the number of bacilli in the lung and sputum which leads to a higher reproductive rate of the bacteria. Status and grade of sputum smear, lung cavitations and time of treatment initiation determine the infectiousness of the index cases (34, 35). The number of bacilli found in the sputum of smear-positive patients makes the patients more infectious (4, 36). This implies that policy makers should design the way families of TB patients could be screened regularly.

High proportion of overcrowding described by few numbers of rooms and larger family size with the presence of a higher proportion of smear-positive and lung cavitations among the delayed TB patients would farther intensify TB transmission in the study area. The risk of TB transmission varies depending on the closeness of contact with an infectious TB index case where the increased closeness of contact, poorly ventilated and overcrowded dwellings were associated with the increased transmission (37, 38).

In this study HIV positive patients had a higher rate of risk of transmission compared to HIV negative TB patients which was similar with studies from Kenya (39) and US () but contrary to Tanzania (37). A study in Kenya and US indicated that risk of TB infection was increased with increasing HIV prevalence over time and in Tanzania the TB annual risk of infection remained unchanged despite an increase in HIV prevalence (39, 40). Furthermore; contrary to our findings studies had also indicated lower rate of smear positivity and lung cavitations among HIV positive patients due to the absence of delayed-type hypersensitivity response (41, 42). The observed difference or contrary might be due to all of HIV infected patients participated in this study had started antiretroviral therapy which could improved immune status of the patients and this leads to the increased risk of transmission or lung
cavitations.

The findings of the current study should be interpreted with the following limitations. The duration of treatment delay may be influenced by recall bias which may affect the magnitude of patient delay. Effort was made to minimize the bias using different methods. Firstly, we have used local calendars of holidays, special events (marriage, death, birth date and epiphany) which enable the patients to remember the exact date. Second, the study participants were recruited and interviewed immediately after their diagnosis. Furthermore, we do not believe that this bias would affect the association between sputum smear positivity, having a pulmonary cavity and clinical severity with increasing duration of treatment delay as it would be the same for all patients. Rather than using actual disease transmission measures, we used two proxy measures which could potently bring a worry. However, these two measures have been well associated with TB transmission and have been used by previous studies to measure the risk of transmission (22, 25, 26).

**Conclusion And Recommendations**

Delayed initiation of TB treatment increases clinical severity and risk of transmission (i.e, increased smear positivity and lung cavitations). Furthermore; the risk of transmission was higher among those who have more than three family members, lower in TB patients having at least two rooms and among HIV negative TB patients. These findings imply that the regional government should work to reduce the long-delayed treatment initiation through strengthening its diagnostic efficiency and implementation of rapid diagnostic tools at the primary health care units. Delayed and non-delayed patients should be clearly identified during treatment initiation for better clinical management during the treatment follow up period. Future study on the same topic should use real transmission measures so that it addresses one of the limitations of the current study.

**Declarations**

**Authors’ contributions**

KT wrote the proposal, participated in data collection and drafted the manuscript. AM, GB, GM and NB commented the proposal with great revisions, participated in data analysis and revised drafts of the manuscript.
Conflict of interest
There is no financial and non-financial conflict among the authors.

Funding
No external funder.

Availability of data and materials
All data is contained in the manuscript and other raw data will be provided to readers upon the request to the corresponding author.

Consent for publication
Not applicable.

Ethical consideration
Ethical approval for this study was obtained from Research and Ethical Committee of Addis Ababa University, Aklilu Lemma Institute of Pathobiology. A formal permission letter was also obtained from regional health bureau of Tigray to the selected district health office. Each health facility selected for the study was contacted with permission letter from district health office. Each case diagnosed as TB according to the national guideline was consented in a written form before the interview. To assure confidentiality interview with TB case was held in a private room and the information collected were recorded anonymously.

Acknowledgment
I would like to express my gratitude to Aklilu Lemma Institute of Pathobiology, Addis Ababa University, for giving me the opportunity to undertake my PhD study. I would like also to thank Mekelle University for giving me full sponsorship to study my PhD at Addis Ababa University. I would also like to thank all health professionals working in the health facilities where this study was conducted.

References
1. Ward HA, Marciniuk DD, Pahwa P, Hoeppner VH: Extent of pulmonary tuberculosis in patients diagnosed by active compared to passive case finding. Int J Tuberc Lung Dis. 2004, 8(5):593-597.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999; 282: 677-86.

3. Bjune G: Tuberculosis in the 21st century: an emerging pandemic? Norsk Epidemiology 2005, 15(2):133-139.

4. Kompala T, Shenoi S V, Friedland G. Transmission of Tuberculosis in Resource-Limited Settings. Curr HIV/AIDS Rep. 2013;10:264-72.

5. Beyers N, Gie RP, Schaaf HS, et al. Delay in the diagnosis, notification and initiation of treatment and compliance in children with tuberculosis. Tuberc Lung Dis. 1994;75:260-5

6. Storla DG, Yimer S and Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health. 2008; 8:15. doi: 10.1186/1471-2458-8-15 PMID: 18194573

7. Lin X, Chongsuvivatwong V, Lin L, Geater A, Lijuan R. Dose-response relationship between treatment delay of smear-positive tuberculosis patients and intrahousehold transmission: a cross-sectional study. Trans R Soc Trop Med Hyg. 2008;102:797–804.

8. Virenfeldt J, Rudolf F, Camara C, A Furtado,1 V Gomes,1 P Aaby, E Petersen, C Wejse1, Treatment delay affects clinical severity of tuberculosis: a longitudinal cohort study BMJ Open 2014;4:e004818.

9. Belay M, Bjune G, Ameni G, Abebe F. Diagnostic and treatment delay among Tuberculosis patients in Afar Region, Ethiopia: A cross-sectional study. BMC Public Health. 2012; 12:369. doi: 10.1186/1471-2458-12-369 PMID: 22621312

10. H.N. Aldhubhani, M.I. Mohamed Izham, I. Pazilah 3 and M.S. Anaam. Effect of delay in diagnosis on the rate of tuberculosis among close contacts of tuberculosis patients. EMHJ, 2013;19(10)

11. Mor Z, Kolb H, Lidji M, Migliori GB, Leventhal A. Tuberculosis diagnostic delay and
therapy outcomes of non-national migrants in Tel Aviv, 1998-2008. Euro Surveill. 2013;18(12):20433.

12. Yimer S, Bjune G and Alene G. Diagnostic and treatment delay among pulmonary tuberculosis patients in Ethiopia: a cross sectional study. BMC Infect Dis. 2005; 5: 112.

13. Mengiste M Mesfin, Tesfay W Tasew, Israel G Tareke, Yohannes T Kifle, Witten H Karen and Madeley J Richard. Delays and care seeking behavior among tuberculosis patients in Tigray of northern Ethiopia. Ethiop J Health Dev. 2005;19:7-12.

14. Ethiopian Demographic and Health Survey: 2015/16

15. Demissie M, Lindtjorn B, Berhane Y. Patient and health service delay in the diagnosis of pulmonary tuberculosis in Ethiopia. BMC Public Health. 2002;2:23.

16. Hussen A, Biadgilign S, Tessema F, Mohammed S, Deribe K, Deribew A. Treatment delay among pulmonary tuberculosis patients in pastoralist communities in bale zone, Southeast Ethiopia. BMC Res Notes. 2012;5:320.

17. Takele T, Meaza D, Yemane B, Yigzaw K, Markos A. Long distance travelling and financial burdens discourage tuberculosis DOTs treatment initiation and compliance in Ethiopia: a qualitative study. BMC Public Health. 2013;13:424

18. Ethiopian Demographic and Health Survey: 2015/16

19. Tigray regional health bureau 2017 annual report. 2017/8 Mekelle, Tigray

20. Federal Ministry Of Health Ethiopia, Health Sector Development Programme IV. October 2010.

21. Helena Janols, Ebba Abate, Jonna Idh, Meseret Senbeto, Sven Britton, Shitaye Alemu, Abraham Aseffa, Olle Stendahl & Thomas Schön Early treatment response evaluated by a clinical scoring system correlates with the prognosis of pulmonary tuberculosis patients in Ethiopia: A prospective follow-up study, Scandinavian Journal of Infectious
22. Cheng S, Chen W, Yang Y, Chu P, Liu X, Ping Chu, Xiaoli Liu, Meiguizhao, Weiguo Tan, Li Xu, Qingfang Wu, Hongyun Guan, Jinhong Liu, Haitao Liu, Ray Y. Chen, Zhongwei Jia6,. Effect of Diagnostic and Treatment Delay on the Risk of Tuberculosis Transmission in Shenzhen, China: An Observational Cohort Study, 1993–2010. PLoS ONE. 2013; 8(6): e67516. doi:10.1371/journal.pone.0067516

23. Christian Wejse, Per Gustafson, Jens Nielsen, Victor Francisco Gomes, Peter Aaby, Paul Lehm Andersen & Morten Sodemann. TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course, Scandinavian Journal of Infectious Diseases, 2008; 40:2, 111-120

24. Frauke Rudolf, Grethe Lemvik, Ebba Abate, Jay Verkuilen, Thomas Schön, Victor Francisco Gomes, Jesper Eugen-Olsen, Lars Østergaard & Christian Wejse TBscore II: Refining and validating a simple clinical score for treatment monitoring of patients with pulmonary tuberculosis, Scandinavian Journal of Infectious Diseases, 2013; 45:11, 825-836,

25. Gupta KB, Atreja A) Transmission of tubercles infection and its control in health care facilities. NTI Bulletin, 2006;42: 63–67.

26. Horne DJ, Johnson CO, Oren E, Spitters C, Narita M How soon should patients with smear-positive tuberculosis be released from inpatient isolation? Infection control and hospital epidemiology 2010;31(1): 78-84.

27. Federal Ministry of Health Ethiopia. Guidelines for clinical and programmatic management of TB, leprosy and TB/HIV in Ethiopia. 5th ed. 2012, Addis Ababa, Ethiopia

28. Wejse C, Gustafson P, Nielsen J, et al. TBscore: Signs and symptoms from
tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis 2008;40:111–20.

29. Rudolf F, Lemvik G, Abate E, et al. TBscore II: refining and validating a simple clinical score for treatment monitoring of patients with pulmonary tuberculosis. Scand J Infect Dis 2013;45:825-36.

30. Lawn SD, Afful B, Acheampong JW. Pulmonary tuberculosis:diagnostic delay in Ghanaian adults. Int J Tuberc Lung Dis 1998;2:635-40.

31. Diez MJ, Bleda MJ, Alcaide J, Caloto T, Castells C, Cardenal JL, et al. Determinants of patient delay among tuberculosis case in Spain. Eur J Pub Health. 2005; 343-9. PMid:16014664

32. Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB, Fenton MJ, Kornfeld H. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Immun. 1997; 65 (1): 298–304.

33. Ryan MacLaren Wallace1, J. Steve Kammerer2, Michael F. Iademarco3, Sandy P. Althomsons2, Carla A. Winston1, and Thomas R. Navin1. Increasing Proportions of Advanced Pulmonary Tuberculosis Reported in the United States. Are Delays in Diagnosis on the Rise? Am J Respir Crit Care Med 2009; 180:1016–1022.

34. Erkens CGM, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, Haas W, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J. 2010 Oct;36(4):925–49.

35. Mandalakas A M, Kirchner HL, Lombard C, Walzl G, Grewal HMS, Gie RP, et al. Well quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection. Int J Tuberc Lung Dis. 2012;16(8):1033–9.

36. Schaaf HS, Michaelis IA, Richardson M, BooySEN CN, Gie RP, Warren R, et al. Adult-to-child transmission of tuberculosis: household or community contact? Int J Tuberc
37. Marais BJ, Hesseling AC, Schaaf HS, Gie RP, van Helden PD, Warren RM. Mycobacterium tuberculosis transmission is not related to household genotype in a setting of high endemicity. J Clin Microbiol. 2009;47(5):1338–43.

38. Johnstone-Robertson S, Mark D, Morrow C, Middelkoop K, Chiswell M, Aquino LD, et al. Social Mixing Patterns Within a South African Township Community: Implications for Respiratory Disease Transmission and Control. Am J Epidemiol. 2011;174(11):1246–55.

39. Egwaga S, Cobelens F, Muwinge H, Verhage C, Kalisvaart N, Borgdorff MW. The impact of the HIV epidemic on tuberculosis transmission in Tanzania. AIDS. 2006;20(6):915–21.

40. Odhiambo J, Borgdorff MW, Kiambih F, Kibuga D, Kwamanga D, Ng’ang’a L, et al. Tuberculosis and the HIV epidemic: increasing annual risk of tuberculosis infection in Kenya, 1986-1996. Am J Public Heal. 1999;89:1078–82.

41. Kooi Eng San, Mahayidin Muhamad. PULMONARY TUBERCULOSIS IN HIV INFECTION: THE RELATIONSHIP OF THE RADIOGRAPHIC APPEARANCE TO CD4 T-LYMPHOCYTES COUNT. Malaysian Journal of Medical Sciences, 2001;8:1;34-40

42. Maria de Fátima Militão de Albuquerque, Silvio Cavalcanti de Albuquerque, Antonio Roberto Leite Campelo, Marta Cruz, Wayner V. de Souza, Ricardo A.A. Ximenes and Roberta A.S. de Souza. Radiographic features of pulmonary tuberculosis in patients infected by HIV: is there an objective indicator of co-infection? Revista da Sociedade Brasileira de Medicina Tropical 2001;34:4;369-372.